COLLEGIUM PHARMACEUTICAL, INC

# Signal Note: Eventide COLL Initiation Eventide's $86.9M entry into Collegium suggests confidence in COLL's opioid portfolio repositioning, likely driven by upcoming catalysts around Xtampza ER (abuse-deterrent oxycodone) market penetration and potential label expansions or generic erosion mitigation strategies. The values-based investor's conviction here may reflect COLL's pivot toward pain management solutions with reduced abuse liability, a differentiated narrative in the opioid space. Timing coincides with healthcare reform focus on addiction-resistant formulations, though execution risk remains material given competitive generic pressures and reimbursement headwinds.